1. Home
  2. WT vs AUPH Comparison

WT vs AUPH Comparison

Compare WT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WisdomTree Inc.

WT

WisdomTree Inc.

HOLD

Current Price

$18.37

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.97

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WT
AUPH
Founded
1985
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
WT
AUPH
Price
$18.37
$15.97
Analyst Decision
Hold
Buy
Analyst Count
3
4
Target Price
$17.33
$17.25
AVG Volume (30 Days)
3.3M
1.1M
Earning Date
05-01-2026
05-11-2026
Dividend Yield
0.69%
N/A
EPS Growth
127.27
5075.00
EPS
0.75
2.07
Revenue
$493,753,000.00
$283,055,000.00
Revenue This Year
$35.04
$17.54
Revenue Next Year
$8.68
$15.74
P/E Ratio
$23.27
$7.76
Revenue Growth
15.43
20.38
52 Week Low
$8.18
$7.29
52 Week High
$17.87
$16.54

Technical Indicators

Market Signals
Indicator
WT
AUPH
Relative Strength Index (RSI) 70.09 60.86
Support Level $13.07 $14.56
Resistance Level N/A $16.28
Average True Range (ATR) 0.74 0.47
MACD 0.37 0.04
Stochastic Oscillator 96.85 75.84

Price Performance

Historical Comparison
WT
AUPH

About WT WisdomTree Inc.

WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: